Regulation

PhRMA sues CMS over drug pricing policy

Photo: Kevin Dietsch/Getty Images

October 19, 2026 2 min read

The pharma trade group claims CMS exceeded its authority with the Medicare Part B pricing model.

Arguing that it is unlawful and exceeds the agency’s authority, the Pharmaceutical Research and Manufacturers of America (PhRMA) is challenging the Center for Medicare & Medicaid Services’ (CMS) Most Favored Nation (MFN) policy in Medicare Part B.

According to a lawsuit filed by the trade group on October 7 in

CMS, Compliance, Healthcare, Industry, Medicaid, Medicare, Medicare Advantage, Pharma, Regulation, US Content

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial

What’s included:

Every new article, plus our 5,000+ archive
Daily regulatory insight and guidance
Exclusive interviews and in-depth analysis
Coverage of industry-leading events and conferences
All podcasts and videos, featuring industry experts
The full set of Rules Navigator tools
An ad-free experience

A photo of several blue prescription drug capsules in a white pharmacist tray.

Regulation

CMS finalizes Medicare Part B drug pricing model to cut costs

Premium

CMS finalized a mandatory Medicare Part B payment model using pricing benchmarks to test lower drug costs while maintaining care quality.

Kevin Kinsella

Oct 2, 2026

A photo of multiple shelves in a pharmacy packed with a variety of styles of medication prescription bottles.

Regulation

CMS says all states applied to its Medicaid drug pricing model initiative

According to CMS, all 50 states, DC, and Puerto Rico have applied to join the CMS GENEROUS Model, which aims to lower Medicaid prescription drug costs through MFN pricing.

Kevin Kinsella

Sep 24, 2026